Preclinical application of a dual-tracer SPECT approach with [111In]In-PSMA-I&T and [99mTc]Tc-DPD for improved diagnosis of prostate cancer

Le résumé fourni par la source

Abstract Background Many high-risk prostate cancer (PCa) patients need to undergo 99m Tc-based bone scintigraphy as part of conventional diagnostics to assess metastasis to the bone. Besides, targeting the prostate-specific membrane antigen (PSMA) has proven to be very effective for theranostic approaches in PCa in recent years. Therefore, we recognized the high clinical potential of a dual-tracer approach, simultaneously targeting PSMA-expressing lesions and PSMA-negative bone anomalies. In a preclinical PCa model, we aimed at concurrent administration and dual-isotope single-photon emission computed tomography (SPECT) of two radiotracers labeled either with Indium-111 ( 111 In) or Technetium-99m ( 99m Tc). Separate depiction of the signals should illustrate the different biodistribution of [ 111 In]In-PSMA-I&T and 99m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ([ 99m Tc]Tc-DPD) in the animal. Results Temporally parallel radiosyntheses and analysis of [ 111 In]In-PSMA-I&T and [ 99m Tc]Tc-DPD were successfully established. Co-incubation studies were conducted with the radioligand stock solutions as well as in vitro experiments using LNCaP cells. LNCaP xenograft-bearing CB17-SCID mice were injected almost simultaneously with [ 111 In]In-PSMA-I&T and [ 99m Tc]Tc-DPD and scanned at different time points after injection (2–3 h and 23 h p.i.) on a Siemens Inveon µ SPECT/CT. Thereafter, mice were subjected to biodistribution studies. Co-incubation experiments revealed no mutual detrimental effects on radioligand purities. In vitro studies confirmed that the presence of DPD has no influence on [ 111 In]In-PSMA-I&T binding and internalization into PSMA-expressing LNCaP cells. By application of three different acquisition windows ( 99m Tc: 126–154 keV, 111 In: 221–269 keV, open: 80 - 270 keV) radionuclide-specific uptake could be observed and distinguished in the PSMA-expressing xenografts ([ 111 In]In-PSMA-I&T) and in the bones ([ 99m Tc]Tc-DPD). Biodistribution data corroborated these results. Conclusions Dual-tracer SPECT imaging of PSMA-positive xenografts and PSMA-negative bone structures with [ 111 In]In-PSMA-I&T and [ 99m Tc]Tc-DPD, respectively, was successfully realized in this preclinical approach. The positive results of this proof-of-concept study indicate a potentially prompt and successful transfer to clinical settings in which PSMA − bone lesions can be identified besides the PSMA + primary tumor and metastases in a single SPECT/CT scan. This in turn could reduce scan time, CT dose and costs per patient, and provide important insights into tumor biology and improve stratification and treatment of PCa patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.